



Simultaneously analyzes over 5,500 of naturally occurring and synthetic signal peptides
Significant improvements in protein yield (up to 500% in external validations)
Especially powerful for difficult-to-express proteins that hinder development
Compatible with expression optimization of any mammalian protein production system: from mRNA therapies to synthetic proteins

May 20, 2025
Veli-Pekka Jaakola joins Avenue Biosciences as Chief Technology Officer
October 22, 2024
Avenue Biosciences Raises $2.5M Seed to Scale AI-Enhanced Protein Engineering
October 7, 2024
Avenue Biosciences Welcomes Industry Experts to Advisory Board for Market Insights and Focused Growth

Our platform is a unique combination of high-throughput chemistry and synthetic biology, powered by machine learning and AI algorithms.
It is the most powerful solution to engineering N-terminal signal peptides: An element significantly underutilized in protein biologics.
Enhance any protein production system: From protein biologics and biosimilars to any mammalian protein-based biotechnology tools.
ENABLE PRODUCTION OF DIFFICULT-TO-EXPRESS PROTEINS
ENHANCE PROTEIN, mRNA & VIRAL THERAPIES
SINGLE CHAIN PROTEIN EXPRESSION OPTIMIZATION
MULTI-CHAIN PROTEIN EXPRESSION OPTIMIZATION (mABS, ANTIBODIES)
BOOSTING VACCINE & DRUG DISCOVERY
MAMMALIAN CELL LINE DEVELOPMENT
Increase the success of therapeutic and biotechnology development with precise, scalable protein engineering

Reduce time-to-market and production costs in pre-clinical therapeutic development

Gain a critical advantage and unique IP with novel molecular components




